Benzinga | Dec 21, 2021 02:56PM EST

Aridis Pharma Press Release Highlights Comments By Co. CEO During Fox Business Interview

Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that Vu Truong, Ph.D., Chief Executive Officer, was interviewed on Varney & Co., hosted by Stuart Varney, on Fox Business.

Key Highlights:

* AR-703, one of the components of the AR-701 cocktail, binds to the 'S2' stalk region of coronavirus spike proteins that is responsible for viral fusion and entry into host cells, and binds to the Omicron variant with no loss in affinity as compared to the original Wuhan strain.

* In vitro neutralization studies using live coronaviruses showed that AR-701 achieved broad, potent neutralization against all SARS-CoV-2 variants tested, as well as SARS, MERS, and the seasonal 'common cold' betacoronaviruses.

* In vivo data with multiple animal challenge models that are widely used to evaluate COVID-19 treatments support AR-701's broad efficacy.

* AR-701 is engineered to be long-acting and is expected to provide relevant drug levels for up to 1 year from prophylactic or therapeutic treatment.

Watch the full interview: https://video.foxbusiness.com/v/6287991662001#sp=show-clips